In this issue:
- Sotorasib for KRAS mutations
- EGFR-mutated NSCLC rates in Māori and Pacifica
- Leptomeningeal metastases after checkpoint blockade
- Durvalumab for stage III EGFR-mutated NSCLC after chemoradiotherapy
- Metformin plus chemoradiotherapy in locallyadvanced NSCLC
- Prognostic factors and pembrolizumab in advanced NSCLC
- Real-world utility of nextgeneration sequencing
- Age disparities in lung cancer survival in NZ
- SABR in T1-2N0M0 SCLC
- International differences in lung cancer survival
Please login below to download this issue (PDF)